Summary. No significant differences were found in the erythrocyte 2.3-DPG concentration between 14 normals (16.82:]:0.66 ~moles 2.3-DPG/g Hb) and 44 diabetic patients (16.22~:0.38 ~zmoles 2.3-DPG/g Hb).
Since then a widespread interest has arisen in studying the regulatory mechanism of 2.3-DPG synthesis and breakdown in erythrocytes. Several clinical conditions like anaemia [6] , acidosis [7, 8, 9] and cardiac disease [10] have been detected, where changes in the 2.3-DPG level of the red blood cell occur. In two communications [11, 12] we have presented preliminary results on the decrease of 2.3-DPG in diabetics in association with a drop in blood glucose. The purpose of this study was to investigate in-vivo and in-vitro the role of blood glucose on the 2.3-DPG level in normals, diabetics and patients with an islet cell tumor and also the in-vitro effects of insulin and tolbutamide. 
Patients and Methods

In-vivo Studies
34 diabetics admitted to hospital and 14 normal subjects (Group I) proven to be nondiabetie by means of a glucose tolerance test were studied. None of the patients was acidotic or suffered from anaemia. Patients with cardiac failure, respiratory or renal insufficiency were not included. The ages varied from 22 to 64 years in the diabetics and from 25 to 60 in the normal controls. 21 diabetics had insulin dependent diabetes and 13 were on oral agents. There was a group of 10 diabetics who had been considerably hyperglycaemic (blood glucose about 300--350 rag/100 ml) yet non-acidotic over a period of more than a week (Group II). At the time of blood sampling for 2.3-DPG measurements the blood glucose concentration was 312 4-17 rag/100 ml • S.E.M. These patients were restudied when their blood glucose was normal (Group III). Another group was examined after they had been in good control for more than a week (Group IV). A fifth group consisted of 11 metabolically well-balanced diabetics with microangiopathy proven by ophthalmoscopy. Venous blood was drawn anaerobically into heparinized syringes in the morning after breakfast, the patients being on their usual antidiabetic regimen.
In addition, two patients were studied who were suspected to have an islet cell tumor. While the patients were fasted overnight, blood was collected at short intervals until symptomatic hypoglycaemia occurred and the procedure was finished by the adminis-E. Standl and H.J. Kolb: 2,3-DPG Fluctuations in Erythroeytes Diabetologia tration of carbohydrates. In both cases an islet cell tumor was found subsequently at surgery. An aliquot of each blood sample was immediately assayed in a blood gas analyser (Corning-EEL Model 165) for pH, standard bicarbonate and p CO S.
In-vitro Studies
Blood was collected as described except EDTA was used as an anticoagulant. Blood aliquots of each individual (about 10 ml) were placed in a dialysis tube which had previously been soaked in water and tied round a plastic tube to keep the top of the dialysis tubing open during dialysis. The dialysis bag was then placed in a 500 ml Erlenmeyer flask and dialysed against 50 volumes of an isotonic solution containing 8 g sodium chloride, 0.4 g potassium chloride and 0.35 g sodium bicarbonate per liter. The pH was adjusted at 7.4 by gasing the solution with a mixture of 5% carbon dioxide in oxygen. The Erlenmeyer flask was incubated in a shaking 37 ~ waterbath. Since the dialysis bag remained open blood samples could easily be withdrawn by a syringe. The actual glucose concentration of the blood sample in the dialysis bag was kept constunt at the desired level by the glucose concentration in the dialysate. Within 30 rain the blood glucose level in markedly hyperglycaemic diabetics (300--400 rag/ 100 ml) dropped to about 80 rag/100 ml, when dialysed against this glucose concentration, thus imitating clinical improvement of diabetes in vitro. For experiments at high glucose (400 rag/100 ml) an aliquot of concentrated glucose solution was added to the blood and dialysed against the dialysate containing 400 mg/ 100 ml glucose.
During the dialysis the oxygen pressure (p 03) was kept constantly above 100 torr as measured with a calibrated oxygen electrode (A 3 Potentiograph Esehweiler, Kiel). The pH of the blood remained unchanged at 7.4. It was an advantage of the dialysis system, that in the dialysis bag the initial blood lactate concentration of about 1 mM did not increase (actually it decreased by about 20 to 30%), although there was continuous lactate production (as indicated by a gradual increase of the lactate concentration up to 0.25 mM in the dialysate).
For studies in the presence of insulin the dialysis system was disadvantageous. Insulin was mixed with a tracer amount of l~iodine labelled insulin and added to the incubates at a final concentration of 500 ~U/ml. As shown by Brodal [13] only intact insulin is preci. prated by 5% trichloroaeetie acid, whereas the degradation products of insulin remain in the supernatant. These tests with II~5-insulin revealed, that after 30 rain of incubation about 80% of the radioiodine counts were in the dialysate due to dialysis and degradation. Similar results were obtained with native insulin, determined by radioimmunoassay as described by Herbert [14] .
Therefore another in-vitro system was set up for these studies. The blood was simply diluted in four volumes of isotonic 0.02 M Tris buffer, containing sodium chloride and potassium chloride, final pH 7.4 and incubated in a 37 ~ shaking waterbath. Under these conditions we could demonstrate, that after six hours of incubation the insulin concentration was still above 50% of the initial value. To this system glucose was added to get a final concentration of 80 or 400 rag/ 100 ml. Again pH and p 02 remained constant while the lactate concentration increased continuously from 0.2 to 1 m~ during incubation.
Plasma glucose was measured by the Technikon Auto Anlalyser [15] and haemoglobin by the cyanhaemoglobin method [16] . For the estimation of 2.3-DPG and ATP blood was deproteinized in 4 volumes of 5% (W/V) trichloroacetic acid under stirring and centrifuged for 5 rain at 4000 g at room temperature. The clear supernatant of two extractions, containing more than 95% of 2.3-DPG of the red cell, were pooled and further diluted with 9 volumes of 0.2 M Tris buffer pH 7.4 to neutralize the sample. 2.3-DPG was determined enzymatically as described by 1Nygaard (17) . Chemicals and enzymes for the test were purchased from Calbiochem (Cat. No. 869237). In this assay the catalytic effect of 2.3-DPG on the reaction rate of phosphoghicomutase coupled with enolase, pyruvate kinase and lactate dehydrogenase results in a decrease of NADH, which was followed with an Eppendorf photometer at 334 rag. The accuracy and reproducibility of the 2.3-DPG assay was about 4-30/0 . ATP was evaluated by a modified method of Lamprecht and Trautsehold [18] , after the trichloroaeetic acid super. natant had been extracted three times with ether. Since both enzymatic tests require a number of auxiliary enzymes, standards were carried out at the beginning and the end of a series of experiments. Lactate was determined as described by Hohorst [19] . Porcine crystalline insulin and tolbutamide were a gift of Farbwerke Hoeehst, West-Germany.
Results
Assays with blood of normal test persons (Group I, Table 1 ) showed a mean 2.3-DPG level of 16.82 =~ 0.66 ~moles per gram haemoglobin. In normals red cell 2.3-DPG content was found to be constant. Five normal subjects were studied repeatedly over months and were also examined on one day at least six times, before and after meals. The 2.3-DPG concentration did not vary more than q-5%.
Diabetes did not effect the 2.3-DPG level in general, as seen in Table 1 . As long as the metabolic pattern of the diabetes was stable --regardless whether well or poorly controlled --the 2.3-DPG level did not differ significantly from the normal values. The group of 10 permanent hyperglycaemie, non-acidotic diabetics (Group II) showed the same 2.3-DPG concentration as did group IV consisting of 13 other diabetics, who were well controlled at least one week before being studied. a Additional blood glucose determinations in the afternoon sugar (Group III). Table 2 gives the individual values of blood glucose, haemoglobin, 2.3-DPG and pH of group II and III. In most cases the 2.3-DPG value was considerably lower after normalization of blood sugar, while haemoglobin and pH were constant. However, the time at which blood was drawn after normalization of glucose was important, since 2.3-DPG did not remain at the low level. Fig. 1 demonstrates one representative patient of group II. Parallel with Another group of 11 diabetics (Group V) who already had retinal microangiopathy and. were wellcontrolled for some time showed mean 2.3-DPG levels of 17.68~0.60 ~moles 2.3-DPG per gram of haemo. globin (Table 1 ). This value is slightly high when compared r normal patients or diabetics without any evidence of angiopathy. However, at the same time we also observed slightly reduced haemoglobin levels of 14=~0.4 g per 100 ml blood, although none of these E. Standl Fig. 3 . Mean 2.3-DPG concentration of hyperglyeaemic blood from six diabetics incubated fit-vitro in the dialysis system at 37 ~ 10 ml blood from each patient was dialysed against isotonic buffer pH 7.4 containing 80 rag/100 ml glucose (filled circles --@--@--) or 400 rag/t00 ml glucose (squares --[~--[]--). The differences at 5 and 7 h are statistically significant (p < 0.001) hours while being on an extended overnight fast. As Fig. 2 indicates, severe hypoglyeaemia is also associated with a reduction of red cell 2.3-DPG content of about 20%. The role of altering blood glucose concentration on the regulation of 2.3.DPG in normal and diabetic subjects was investigated in-vitro using a dialysis technique described in details in 'Methods'. The blood of seven normal subjects incubated and dialysod either against 400 or 80 mg/100 ml glucose showed no change in the 2.3-DPG level during the seven hour incubation period. In contrast, blood of six hyperglycaemic nonketotie diabetics behaved differently (Fig. 3) . At high glucose concentrations 2.3-DPG was maintained at a constant level (15.08 ~= 1.02 ~moles 2.3-DPG]g haemoglobin ~= S.E.M. at the beginning compared to 14.63 j= 0.66 ~moles 2.3-DPG/g haemoglobin ~ S.E.M. at the end) whereas at low glucose concentrations 2,3.Ds decreased from an initial value of 15.58 ~= 0.75 ~moles 2.3-DPG/g haemoglobin =E S.E.M. to 12.81 ~ 0.74 and to 11.58=[=0.53 ~moles 2/3-DPG/g haemoglobin =~ S.E.M. after 5 and 7 hours of incubation (p-values <0.001). Hence, this in-vitro model of clinical improvement of diabetes --as judged by blood glucose --revealed a similar phenomenon as did diabetic patients during treatment.
A possible effect of insulin and tolbutamide on the 2.3-DPG concentration of hyperglyeaemie blood was investigated in-vitro as described in the 'Methods' section. Blood from three hyperglycaemic diabetics was diluted four times with isotonic Tris buffer, pH 7.4, and incubated at either 400 or 80 mg/10O ml glucose. Three different sets of experiments have been carried out, i.e. without further addition, in the presence of 500 ~U insulin/ml or 0.1 mg tolbutamide/ml incubation volume.
It is noteworthy that the effect of glucose on the 2.3-DPG concentration of hyperglycaemic blood shown in the dialysis experiments, could also be seen with this simple system. No different behavior was observed when insulin or tolbutamide were added. Hence insulin and tolbutamide failed to show an effect on red blood cell 2.3-DPG in this system.
Discussion
The 2.3-DPG concentration of 16.82 • 0.66 ~moles/g haemoglobin obtained for normal subjects is in good agreement with values reported in the literature [8, 20, 21] . In extension of our previous work [11, 12] further evidence was obtained that erythrocytes of diabetics in general contain the same concentration of 2.3-DPG related to haemoglobin as normal nondiabetic subjects, l%ecently R6rth et el. [22] and Alberti et el. [23] published similar results. In contrast, Ditzel [24] observed a significantly lowered oxygen binding affinity of erythrocytes from diabetics and concluded that diabetics in general might have decreased 2.3-DPG levels. It should be mentioned that Ditzel [24] calculated his oxygen dissociation curves assuming that the pH was 7.4 in all his diabetics. If the pH was in fact slightly lower, then the curves would have been normal. Our results demonstrate clearly that the metabolic state of the diabetes has to be considered and that there are pronounced differences between diabetic subjects.
A group of markedly hyperglycaemic patients, (mean blood glucose 312 rag/100 ml) with normal 2.3-DPG levels before treatment showed a phase with a significantly lowered 2.3-DPG concentration of about 20% which occurred concomitant with gradual declining blood glucose values due to treatment. After a few days 2.3-DPG rose again to the original concentrations despite persisting low blood glucose values around 140 mg %. A similar phase of sluggish 2.3-DPG increase was observed by Guest and Rapoport [7] and Alberti et el. [25] who found a delayed normalization of 2.3-DPG in keto-acidotic diabetics although acidosis, which had caused reduced 2.3-DPG levels, had long been corrected.
In-vitro experiments in two different systems, which were carried out with blood from diabetics and normals incubated at high or low glucose concentrations, are in good agreement with our in vivo results. The quick reduction of glucose to about 80 mg/100 ml due to dialysis or dilution of blood from hyperglycaemic patients appears to be responsible for the subsequent decrease of 2.3-DPG in erythroeytes during the seven hour incubation period. The same blood sample incubated at 400 mg/100 ml glucose or blood of normal subjects did not show this phenomenon. In addition Travis et al. [26] demonstrated that the 2.3-DPG content of normal human red cells incubated two hours with very high glucose concentrations, i.e. 900 mg/ 100 ml, was somewhat lower compared with incubations at 90 mg/100 ml glucose.
Adding a high dose of insulin or tolbutamide to the in-vitro system did not effect the 2.3-DPG concentration in erythrocytes. Therefore it is not likely that the observed decrease in the 2.3-DPG level during treatment is due to administered insulin or tolbutamide. This result is in agreement with recent binding studies by Cuatrecasas [27] , who demonstrated that insulin does not interact with human erythroeytes.
Considering the effect of rapid blood glucose changes it was not surprising that diabetics with retinal angiopathy, but being in stable metabolic control for a longer period had quite normal 2.3-DPG levels. The small enhancement of 2.3-DPG values is essentially the result of a slightly reduced haemoglobin concentration in the blood of these patients [6] .
It was learnt from the two patients with marked spontaneous hypoglycaemia, that the steady-state level of red cell 2.3-DPG is altered not only by a blood glucose drop from high to normM but also from normal to very low.
Our data suggest, that the glycolytic metabolism of the red cell can adapt to different blood sugar levels, A drop in blood glucose is associated with an intermittert reduction of 2.3-DPG, the main energy rich phosphate in erythrocytes. There is no evidence, how that occurs in detail. It could be due to an increased break-down or decreased synthesis of 2.3-DPG or by. passing of the 2.3-DPG step. Since for the last possi. bility changes in red cell ATP/ADP ratio are relevant, it should be noted, that in all cases the ATP concentration remained constant.
The observed fluctuations in 2.3-DPG concentration of about 20% in a selected group of diabetics and during hypoglycaemia are of the same order of magnitude as found in other known clinical conditions like anaemia [6] . Theoretically, a decrease in 2.3-DPG of this amount should diminish oxygen release in the peripheral tissue at any given partial pressure of oxygen. Since the 2.3-DPG content is mainly influenced by changes in blood sugar and not by the actual level these data might be pertinent for poorly controlled, unstable diabetics, with frequently varying high and very low blood sugar values. If these observations are a connecting link between metabolic control of diabetes and the known hypoxic changes in early microangiopathy remains still open to question.
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